{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T04:23:38Z","timestamp":1728620618593},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Das Rezidivrisiko von Patienten mit einem muskelinvasiven Harnblasenkarzinom (MIBC) nach radikaler Zystektomie ist abh\u00e4ngig vom pathologischen Tumorstadium. Ein hohes Risiko weisen insbesondere Patienten mit einer lymphonodalen Metastasierung (pN+), lokal fortgeschrittenem (\u2265pT3) oder residuellem muskelinvasivem Tumor trotz neoadjuvanter Chemotherapie auf. Aktuell nimmt die Bedeutung einer adjuvanten Therapie mit Immun-Checkpoint-Inhibitoren (ICI) im Rahmen perioperativer systemtherapeutischer Konzepte zu. Die Indikationsstellung bei dem derzeit in der Europ\u00e4ischen Union zugelassenen PD-1-Inhibitor (\u201eprogrammed cell death\u00a01\u201c) Nivolumab erfordert die Expressionsbestimmung des PD-L1 (\u201eprogrammed cell death ligand\u00a01\u201c)-Proteins mittels Immunhistochemie im Tumorgewebe. Mit Fokus auf MIBC-Patienten mit hohem Rezidivrisiko ergeben sich neue Fragen in Bezug auf die Durchf\u00fchrung und Interpretation der PD-L1-Testung. Eine interdisziplin\u00e4re Expertengruppe aus Deutschland hat relevante Fragestellungen aus klinisch-pathologischer Sicht diskutiert und praxisnahe Handlungsempfehlungen erarbeitet, die die Implementierung einer validierten und qualit\u00e4tsgesicherten PD-L1-Testung entlang der zugelassenen Indikationen im klinischen Alltag erleichtern sollen.<\/jats:p>","DOI":"10.1007\/s00120-024-02416-1","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T12:02:15Z","timestamp":1724673735000},"page":"1019-1027","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Deutscher Expertenkonsens zur PD-L1-Testung (\u201eprogrammed cell death ligand\u00a01\u201c) in der perioperativen Systemtherapie des muskelinvasiven Blasenkarzinoms","German expert consensus on programmed cell death ligand\u00a01 (PD-L1) testing in perioperative systemic therapy of muscle invasive bladder cancer"],"prefix":"10.1007","volume":"63","author":[{"given":"G.","family":"Niegisch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bolenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Doehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Gakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"M\u00fcller-Huesmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Roghmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Schwamborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Tiemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Retz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"key":"2416_CR1","volume-title":"Krebs in Deutschland f\u00fcr 2017\/2018","author":"Robert-Koch-Institut (RKI)","year":"2021","unstructured":"Robert-Koch-Institut (RKI) (2021) Harnblase. In: Krebs in Deutschland f\u00fcr 2017\/2018 (https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebs_in_Deutschland\/kid_2021\/krebs_in_deutschland_2021.pdf?__blob=publicationFile)"},{"key":"2416_CR2","volume-title":"Muscle-invasive and metastatic bladder cancer","author":"JA Witjes","year":"2021","unstructured":"Witjes\u00a0JA et\u00a0al (2021) Muscle-invasive and metastatic bladder cancer (https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Muscle-Invasive-Bladder-Cancer-2023.pdf)"},{"key":"2416_CR3","volume-title":"Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms. Langversion 2.0 (Stand: M\u00e4rz 2020), AWMF-Registernr.:032\/038OL","author":"S3-Leitlinie","year":"2020","unstructured":"S3-Leitlinie (2020) Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms. Langversion 2.0 (Stand: M\u00e4rz 2020), AWMF-Registernr.:032\/038OL (https:\/\/register.awmf.org\/assets\/guidelines\/032-038OLl_S3_Harnblasenkarzinom_2020-04-verlaengert.pdf)"},{"issue":"2","key":"2416_CR4","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.juro.2006.03.038","volume":"176","author":"RE Hautmann","year":"2006","unstructured":"Hautmann\u00a0RE et\u00a0al (2006) Cystectomy for transitional cell carcinoma of the bladder: results of a\u00a0surgery only series in the neobladder era. J\u00a0Urol 176(2):486\u2013492","journal-title":"J Urol"},{"issue":"4","key":"2416_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.euo.2022.04.008","volume":"5","author":"PJ Hensley","year":"2022","unstructured":"Hensley\u00a0PJ et\u00a0al (2022) Contemporary staging for muscle-invasive bladder cancer: accuracy and limitations. Eur Urol Oncol 5(4):403\u2013411","journal-title":"Eur Urol Oncol"},{"key":"2416_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00120-022-01983-5","author":"J Lewerich","year":"2022","unstructured":"Lewerich\u00a0J et\u00a0al (2022) Stellenwert der Immuntherapie in der perioperativen Behandlung des lokalisierten muskelinvasiven Harnblasenkarzinoms. Urologie. https:\/\/doi.org\/10.1007\/s00120-022-01983-5 (Value of immunotherapy in the perioperative treatment of localized muscle invasive bladder cancer)","journal-title":"Urologie"},{"issue":"2","key":"2416_CR7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41585-020-00404-6","volume":"18","author":"DM Jiang","year":"2021","unstructured":"Jiang\u00a0DM et\u00a0al (2021) Defining cisplatin eligibility in patients with muscle-invasive bladder cancer. Nat Rev Urol 18(2):104\u2013114","journal-title":"Nat Rev Urol"},{"issue":"22","key":"2416_CR8","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin\u00a0DF et\u00a0al (2021) Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N\u00a0Engl J Med 384(22):2102\u20132114","journal-title":"N Engl J Med"},{"issue":"Suppl.","key":"2416_CR9","doi-asserted-by":"publisher","first-page":"LBA443","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA443","volume":"6","author":"MD Galsky","year":"2023","unstructured":"Galsky\u00a0MD et\u00a0al (2023) Extended follow-up results from the CheckMate 274 trial. J\u00a0Clin Oncol 6(Suppl.):LBA443\u2013LBA443","journal-title":"J Clin Oncol"},{"key":"2416_CR10","series-title":"presented at the annual congress of the European Association of Urology 2024, April 5, Paris","volume-title":"Extended follow-up results from the CheckMate 274 trial","author":"Galsky","year":"2024","unstructured":"Galsky et\u00a0al (2024) Extended follow-up results from the CheckMate 274 trial. presented at the annual congress of the European Association of Urology 2024, April 5, Paris"},{"key":"2416_CR11","unstructured":"EMA Recommends Extension of Therapeutic Indications for Nivolumab. https:\/\/www.esmo.org\/oncology-news\/ema-recommends-extension-of-therapeutic-indications-for-nivolumab3"},{"key":"2416_CR12","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00120-022-01870-z","volume":"61","author":"CH Ohlmann","year":"2022","unstructured":"Ohlmann\u00a0CH et\u00a0al (2022) Qualit\u00e4tssicherung zur Therapie des muskelinvasiven und metastasierten Harnblasenkarzinoms in Deutschland. Urologie 61:1351\u20131364","journal-title":"Urologie"},{"key":"2416_CR13","unstructured":"PD-L1-Portal. https:\/\/www.pdl1portal.eu\/"},{"issue":"3","key":"2416_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.euf.2015.03.004","volume":"1","author":"AS McDaniel","year":"2016","unstructured":"McDaniel\u00a0AS et\u00a0al (2016) Expression of PDL1 (B7-H1) before and after neoadjuvant chemotherapy in urothelial carcinoma. Eur Urol Focus 1(3):265\u2013268","journal-title":"Eur Urol Focus"},{"issue":"6","key":"2416_CR15","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/his.13710","volume":"73","author":"JJ De Jong","year":"2018","unstructured":"De Jong\u00a0JJ et\u00a0al (2018) Concordance of PD-L1 expression in matched urothelial bladder cancer specimens. Histopathology 73(6):983\u2013989","journal-title":"Histopathology"},{"issue":"2","key":"2416_CR16","first-page":"162","volume":"22","author":"T Gevaert","year":"2021","unstructured":"Gevaert\u00a0T et\u00a0al (2021) PD-L1 testing for urothelial carcinoma: interchangeability, reliability and future perspectives. Curr Drug Targets 22(2):162\u2013170","journal-title":"Curr Drug Targets"},{"issue":"2","key":"2416_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.eururo.2022.10.020","volume":"83","author":"F Erlmeier","year":"2023","unstructured":"Erlmeier\u00a0F et\u00a0al (2023) Spatial Immunephenotypes of distant metastases but not matched primary urothelial carcinomas predict response to immune checkpoint inhibition. Eur Urol 83(2):133\u2013142","journal-title":"Eur Urol"},{"issue":"4","key":"2416_CR18","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00428-021-03094-6","volume":"479","author":"JJ De Jong","year":"2021","unstructured":"De Jong\u00a0JJ et\u00a0al (2021) PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays. Virchows Arch 479(4):705\u2013713","journal-title":"Virchows Arch"},{"key":"2416_CR19","doi-asserted-by":"publisher","first-page":"920021","DOI":"10.3389\/fimmu.2022.920021","volume":"13","author":"X Zhao","year":"2022","unstructured":"Zhao\u00a0X et\u00a0al (2022) From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1\/PD-L1 blockades. Front Immunol 13:920021","journal-title":"Front Immunol"},{"issue":"11","key":"2416_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000527879","volume":"2023","author":"C Bolenz","year":"2023","unstructured":"Bolenz\u00a0C et\u00a0al (2023) Increasing biomarker guidance in the treatment of urothelial carcinoma: systematic review of international clinical trials. Urol Int 2023(11):1\u20139. https:\/\/doi.org\/10.1159\/000527879","journal-title":"Urol Int"},{"issue":"22","key":"2416_CR21","doi-asserted-by":"publisher","first-page":"690","DOI":"10.21037\/atm.2019.10.24","volume":"7","author":"M Eckstein","year":"2019","unstructured":"Eckstein\u00a0M et\u00a0al (2019) PD-L1 assessment in urothelial carcinoma: a\u00a0practical approach. Ann Transl Med 7(22):690","journal-title":"Ann Transl Med"},{"issue":"4","key":"2416_CR22","first-page":"173","volume":"34","author":"R Mazzucchelli","year":"2012","unstructured":"Mazzucchelli\u00a0R et\u00a0al (2012) Clinicopathological significance of lymphovascular invasion in urothelial carcinoma. Anal Quant Cytopathol Histpathol 34(4):173\u2013179","journal-title":"Anal Quant Cytopathol Histpathol"},{"issue":"5","key":"2416_CR23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00428-019-02610-z","volume":"475","author":"K Schwamborn","year":"2019","unstructured":"Schwamborn\u00a0K et\u00a0al (2019) Multicentric analytical comparability study of programmed death-ligand\u00a01 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. Virchows Arch 475(5):599\u2013608","journal-title":"Virchows Arch"},{"issue":"7","key":"2416_CR24","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/PAS.0000000000001264","volume":"43","author":"H Reis","year":"2019","unstructured":"Reis\u00a0H et\u00a0al (2019) PD-L1 expression in Urothelial carcinoma with predominant or pure variant histology: concordance among three commonly used and commercially available antibodies. Am J Surg Pathol 43(7):920\u2013927","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2416_CR25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/PAP.0000000000000309","volume":"28","author":"E Comp\u00e9rat","year":"2021","unstructured":"Comp\u00e9rat\u00a0E et\u00a0al (2021) The genitourinary pathology society update on classification of variant Histologies, T1 substaging, molecular taxonomy, and immunotherapy and PD-L1 testing implications of Urothelial cancers. Adv Anat Pathol 28(4):196\u2013208","journal-title":"Adv Anat Pathol"},{"key":"2416_CR26","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow\u00a0DB et\u00a0al (2021) PD-L1 as a\u00a0biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncology 18:345\u2013362","journal-title":"Nat Rev Clin Oncology"},{"key":"2416_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000383","author":"V Bahlinger","year":"2022","unstructured":"Bahlinger\u00a0V et\u00a0al (2022) Immunotherapy in genitourinary cancers: role of surgical pathologist for detection of Immunooncologic predictive factors. Adv Anat Pathol. https:\/\/doi.org\/10.1097\/PAP.0000000000000383","journal-title":"Adv Anat Pathol"},{"key":"2416_CR28","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s00292-022-01102-3","volume":"43","author":"K J\u00f6hrens","year":"2022","unstructured":"J\u00f6hrens\u00a0K et\u00a0al (2022) Ringversuche \u2013 ein zentrales Mittel der externen Qualit\u00e4tssicherung. Pathologie 43:346\u2013350","journal-title":"Pathologie"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02416-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-024-02416-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02416-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T17:03:02Z","timestamp":1728579782000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-024-02416-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2416"],"URL":"https:\/\/doi.org\/10.1007\/s00120-024-02416-1","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"type":"print","value":"2731-7064"},{"type":"electronic","value":"2731-7072"}],"subject":[],"published":{"date-parts":[[2024,8,26]]},"assertion":[{"value":"15 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"G.\u00a0Niegisch: Vortragst\u00e4tigkeit: Roche Pharma, MEDAC, Pfizer, BMS, AstraZeneca, Astellas, Merck, medac; beratende Funktion: Roche Pharma, Sanofi, BMS, Merck, Pfizer, Ipsen, Janssen-Cilag, AstraZeneca, Astellas. Reisekostenzusch\u00fcsse, Kongressregistrierungen: Roche Pharma, Pfizer, Merck, AstraZeneca, Janssen-Cilag. C.\u00a0Bolenz: Vortragst\u00e4tigkeit: Bayer, medac. Vortragst\u00e4tigkeit\/Forschungsf\u00f6rderung: AstraZeneca, Janssen-Cilag, Roche Pharma. Forschungsf\u00f6rderung: Cepheid, ERBE Elektromedizin; beratende Funktion (2021-23): BMS. C.\u00a0Doehn: Aktienbesitz: AstraZeneca. Beratende Funktion: Apogepha, BMS, Eisai, EUSA Pharm, Ipsen, Merck Serono, MSD, Novartis, Pfizer. Vortragst\u00e4tigkeit\/Reisekostenzusch\u00fcsse (2021-23): Apogepha, BMS, Ipsen, MSD, Novartis, Pfizer, Roche Pharma. G.\u00a0Gakis: Beratende Funktion: Astellas, BMS, Bayer, Leo Pharma, medac, Merck Serono, MSD, QED Therapeutics, Photocure. Vortragst\u00e4tigkeit: AstraZeneca, Erbe Elektromedizin, IPSEN Pharma, Leo Pharma, medac, MSD, Roche, Janssen-Cilag, CEA Alliance. A.\u00a0Hartmann: Vortragst\u00e4tigkeit\/beratende Funktion: Abbvie, Agilent, AstraZeneca, Biocartis, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Gilead, Illumina, Ipsen, Janssen, Lilly, Merck, MSD, Nanostring, Novartis, Pfizer, Qiagen, QUIP GmbH, Roche, Sanofi, 3DHistotech. Forschungsf\u00f6rderung: AstraZeneca, Biocartis, Cepheid, Gilead, Illumina, Janssen, Nanostring, Novartis, Owkin, Qiagen, QUIP GmbH, Roche, Sanofi. H.\u00a0M\u00fcller-Huesmann: Beratende Funktion: Roche Pharma, BMS, Janssen-Cilag, MSD, Servier, AstraZeneca, Seagen, Ipsen, Merck, 420 pharma. Honoraria: Roche Pharma, BMS, Janssen-Cilag, AstraZeneca, Boehringer-Ingelheim, Ipsen, Pfizer, Servier, Merck. Forschungsf\u00f6rderung: Roche Pharma, BMS. H.\u00a0Reis: Forschungsf\u00f6rderung: BMS, Molecular health. Beratende Funktion: BMS, Boehringer Ingelheim, GlaxoSmithKline, Janssen-Cilag, Merck, Novartis, Roche Pharma, Sanofi. Vortragst\u00e4tigkeit\/Reisekostenzusch\u00fcsse: AstraZeneca, BMS, Boehringer Ingelheim, Chop GmbH, Diaceutics, GlaxoSmithKline, HUeG, Janssen-Cilag, MCI, Merck, Novartis, Roche Pharma, Sanofi, Wolfsburg Klinikum. F.\u00a0Roghmann: Beratende Funktion: Janssen-Cilag, Roche Pharma, Merck, Pfizer. K.\u00a0Schwamborn: Beratende Funktion\/Vortragst\u00e4tigkeit: Roche Pharma, BMS, MSD, Merck. K.\u00a0Tiemann: Honoraria\/Vortragst\u00e4tigkeit: BMS, AstraZeneca, MSD, Roche Pharma. M.\u00a0Retz: Honoraria: Astellas, AstraZeneca, Bayer, BMS, Eisai, Janssen-Cilag, Merck, MSD, Pfizer, Roche Pharma. Beratende Funktion: Astellas, AstraZeneca, BMS, Gilead, Janssen-Cilag, Merck, MSD, Pfizer, Roche Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. Aus Gr\u00fcnden der Lesbarkeit wird das generische Maskulinum verwendet. Damit sind alle Geschlechter gleicherma\u00dfen gemeint.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}